Servier Reports Strong Growth and Confirms 2030 Forecast

Servier has announced its financial results for the 2024/25 fiscal year, revealing a 16.2% rise in Group revenues to €6.9 billion. This growth was largely driven by increased sales in oncology, especially in the United States. Key developments included partnership agreements in oncology and neurology that bolstered Servier's R&D focus on rare diseases.

Olivier Laureau, President of Servier, highlighted this achievement as a step towards the company's 2030 objectives, emphasizing the significance of its innovation strategy and international expansion. Operating EBITDA grew significantly by 47.2% to €1.9 billion, with an EBITDA margin of 28.2%.

Oncology now contributes 32.2% of the Group's revenue, boosted by the US launch of Voranigo®. The US market, a crucial growth driver, saw revenues increase by 70.3%. Servier remains optimistic about meeting its global revenue target of €10 billion by 2030.